Skip to main content
OpenTrials

Clinical trial condition

Respiratory Syncytial Virus Infections

Explore clinical trials studying Respiratory Syncytial Virus Infections. Study availability and eligibility vary by location and protocol.

144 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Syncytial Virus Infections trial results

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

NCT02878330

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Anaheim, California, United States
  • Research Site Anaheim, California, United States
  • Research Site Downey, California, United States
View all 161 locations
View Trial Details
Completed

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

NCT02956837

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Ghent, Belgium
  • GSK Investigational Site Tallinn, Estonia
  • GSK Investigational Site Tartu, Estonia
  • GSK Investigational Site Clermont-Ferrand, France
View Trial Details
Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

NCT02325791

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Regeneron Investigational Site Birmingham, Alabama, United States
  • Regeneron Study Site Mobile, Alabama, United States
  • Regeneron Study Site Little Rock, Arkansas, United States
  • Regeneron Study Site Anaheim, California, United States
View all 205 locations
View Trial Details
Completed

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02794870

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program La Jolla, California, United States
  • Usc La Nichd Crs Los Angeles, California, United States
  • Univ. of Colorado Denver NICHD CRS Aurora, Colorado, United States
  • Rush Univ. Cook County Hosp. Chicago NICHD CRS Chicago, Illinois, United States
View Trial Details
Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

NCT02360475

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site Lenexa, Kansas, United States
  • GSK Investigational Site Lexington, Kentucky, United States
View Trial Details

Related conditions